Some types of male hypogonadism can be treated with testosterone replacement therapy (TRT). Male hypogonadism is a condition in which clinical symptoms occur due to testosterone deficiency (69). Male hypogonadism, which may arise from multiple etiologies including androgen-deprivation therapy (ADT), has been reported as a risk factor for acquired LQTS and the occurrence of TdP. This has been proven in a dog model, showing that the Ito current density of the RV epicardium is significantly higher in males than in females, culminating in increased transmural dispersion of repolarization (4). Another recently published case study by Sichrovsky et al. (64) has demonstrated the development of a previously unrecognized Brugada pattern and SCD in a genetic female living as a transgender male through the use of exogenous testosterone.
While the connection is not fully understood, it is important to monitor changes and talk to a doctor if a rapid heart rate occurs. Anxiety, stress, or caffeine use can also raise heart rate. This sudden rise might trigger heart-related symptoms in some people. Testosterone injections, especially short-acting ones, can cause hormone levels to spike quickly.
It may raise blood pressure, speed up the heart rate, and increase the risk of blood clots. Fast heart rate is less common but still reported in some clinical studies and patient databases. Studies show that TRT can cause an increased heart rate in some people, but it is not a common or widespread effect. This is the part of the body that controls the "fight or flight" response, which includes increased heart rate and blood pressure.
Hopefully, a randomized controlled trial, sufficiently powered to look at cardiovascular outcomes in a wide range of hypogonadal men receiving TRT, will be under way. Thus, expanded research efforts are needed to adequately address both the clinical and biological complexity of the relationship between androgens and CVD. In the absence of such data, caution and clear goals for treatment should be discussed with men with known CVD while prescribing TRT. However, this was a small study and there is a need to verify the findings and better understand the functional implications of the observed changes in HDL constituent proteins . Furthermore, efflux capacity was a better predictor of extant coronary artery disease than was HDL-c concentration in a large clinical population.
Exercise training represents a significant perturbation to both the human neuroendocrine and autonomic nervous systems (ANS) (2, 56). Saliva samples were analyzed for concentrations of testosterone (T) and cortisol (C) via enzyme-linked immunosorbent assays.
It is important to note that SCD may occur during early, clinically occult stage of ARVC, which still bears the pathological hallmarks of progressive cardiomyocyte loss and fibrofatty infiltration. These findings have recently been validated in another study by Ren et al. (53) in a different ARVC cohort. While risk stratification traditionally relied on measurements of structural dysfunction and electrophysiological indices (51), there have been recent attempts to identify circulating biomarkers for prediction of arrhythmic risk. The role of testosterone during cardiac ischemia and in the prevention of reperfusion arrhythmias is controversial. In the context of an ischemic insult to the heart, reperfusion that accompanies the opening of a blocked coronary artery may trigger arrhythmias and result in SCD. It was shown that estrogen has beneficial effects by improving cardiac function, preserving calcium homeostasis and inhibiting the mitochondrial apoptotic pathway (44).
Most physiological effects of testosterone are mediated through its interaction with the AR, a ligand-dependent nuclear receptor. Bioavailable testosterone can exert its effects directly on androgen receptors (ARs). Sex hormone–binding globulin (SHBG) is the major carrier protein of testosterone,6 with approximately 60% of testosterone bound to SHBG, and an additional 40% bound to albumin.6 Only 1%-2% of testosterone is unbound or free.7 Although only free testosterone was historically considered to be biologically available, albumin-bound testosterone is now also accepted as being bioavailable, due to its lower binding affinity.7

Gender: Female

Social links